A revised analysis of current and emerging Nano suspension technological approaches for cardiovascular medicine

Background This is an objective critique to give an in-depth description of Nano suspensions. This article is attempting to address the issue of whether or not Nano science is realistic with respect to price, with regards to item costs being added to the endeavor and Lipotropic drugs have proven to be rewarding and Lipo-immunotherapy has proven to be beneficial. In modern times, drug marketing and promotion have become crucial to efficient commercializing of successful molecules, pharmaceutical companies often work to increase the chances of promoting successful drugs, these included cardiovascular drugs because of their widespread usage. Main body Nano suspension is a Nano metric Colloidal Suspension system i.e., Nano suspensions, in the solid form reaches the bloodstream and Nanoparticle colloids readily available to the target cells. All research on Nanostructures is focused on the four primary dimensions, composition, homogeneity, heterogeneity, elasticity, and agglomeration. Researchers are devising ways to deliver medication and other substances to a damaged cell and diseased region, as well as diagnose the body to pinpoint disease and defects, by way of Nanotechnology. Short conclusions The vital analysis of Nano science experiment on Nano suspension is working to achieve the goal of reducing product cost by using Nanotechnology in product development, as it wants to examine the probability of development by utilizing Nanotechnology. The usage of the top-limited technology allows the development of cardiovascular drugs classified under the biopharmaceutical classification system (Class II and Class IV) to use two approaches namely top-down and bottom-up methods.

Has the EU Incentive for Drug Repositioning Been Effective? An Empirical Analysis of the “+1” Regulatory Exclusivity

EU law incentivises drug marketing authorisation holders (MAHs) to find new uses for their compounds (research known as “repositioning”) by offering them an extra year of market protection if the new use is authorised. This extra year, known as the “+1”, was enacted on limited evidence, and no study has examined its effect since it began. Yet, several leading commentators suggest lengthening the +1. This study assesses the effectiveness of the +1 by analysing all the relevant instances of MAHs repositioning their drugs before and after the +1 came into effect. The results show that: (i) 42.2% of MAHs repositioned their drugs before the +1 came into effect, and (ii) once the +1 did come into effect, it did not increase the percentage of MAHs that repositioned their drugs. This study finds that the +1 failed to increase repositioning and then proceeds to consider reform options, including repealing the law. In doing so, this study takes the first steps towards an evidence-based policy for the topic.

Direct to Consumer Pharmaceutical Advertising – Helpful or Harmful?

While direct-to-consumer advertising (DTCA) has been legalized in the United States and New Zealand, the prescribed drug marketing has long reached other places in the world including the Asian regions. Behind the successful profit-making pharmaceutical companies, concerns about public health impacts to the patient and physician counterpart have grown. Evidences illustrated that DTCA increases the volume of prescribing amount through patient demand and that the traditional manner of drug prescribing action has changed. However, the quality of health care trade in the relationship between physician and patient often overlooked and compromised. The systematic review analysed eight studies from five identified search engines using PRISMA guidelines. This review findings demonstrate DTCA implication in term of the health literacy, economic impact and relationship between physician and patient. Physician expressed substantial degree of dissatisfying behaviour when challenged with unnecessary need to prescribe drugs demand by patient. The prominent involvement of policymakers in regulating the guideline and controlling delivery of information in any advertisement related to drugs is direly important.

Leveraging Design Thinking for Pharmaceutical Digital Marketing

Worldwide, the time spent online and in digital media has been increasing, thus becoming the primary source of health and medical information. This phenomenon is driving all business, including the pharmaceutical industry, in gearing toward digital marketing strategies. Developing countries like Thailand still extend existing laws to regulate digital media despite the differences with traditional media, and consumers face the risks of buying drugs illegally and products that overclaim despite stringent pre-approval regulations on drug marketing. This study utilizes design thinking as a human-centric research method to propose appropriate and practical digital marketing guidelines for the pharmaceutical industry, using 53 informants. The problems were that consumers face persuasive risks and the need for reliable sources of drug information. The current regulatory process places a high burden on regulators and the laws that enforce it. However, several new digital strategies such as unbranded information and targeted marketing are not covered by existing laws. Regulations on teleconsultation are also needed, but no legislation currently exists for such activities. And finally, experts have articulated four domains as follows: eRegulations, e-Information sources, and e-Consultation to provide easy access to professionals, and e-Ethics, a supportive mechanism toward ethical drug marketing

Failure of Responsive Regulation? Pharmaceutical Marketing, Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe

“Responsive regulation” has been proposed to offset pharmaceutical industry illicit behavior in areas such as drug marketing based on self-regulation backed up with threats of government sanctions. We explore the efficacy of responsive regulation by tracing recent investigations by the UK pharmaceutical industry self-regulatory authority into the firm Astellas’s illicit promotion of a top-selling prostate cancer drug. Using documentary data, we reveal a ruthless company culture reflected in the illicit, so-called off-label promotion across Europe and the deceptive “impression management” by company managers during the course of investigations in the UK. We argue for a more probing, adversarial and government-led regulatory approach instead of the self-regulatory approach that shields breaching companies from enforcement actions and associated public scrutiny.